Search Results for "erythromycin"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for erythromycin. Results 71 to 80 of 120 total matches.

Anthrax Vaccine

   
The Medical Letter on Drugs and Therapeutics • May 08, 1998  (Issue 1026)
, doxycycline, erythromycin, streptomycin and ciprofloxacin, among others, but resistant to third-generation ...
Now that US Secretary of Defense has decided to vaccinate more than 2 million memebers of the US armed forces against anthrax, US physicians may be asked to answer some questions about the vaccine and the disease.
Med Lett Drugs Ther. 1998 May 8;40(1026):52-3 |  Show IntroductionHide Introduction

In Brief: Telithromycin Hepatotoxicity

   
The Medical Letter on Drugs and Therapeutics • Apr 24, 2006  (Issue 1233)
Publication Telithromycin Hepatotoxicity IN BRIEF Telithromycin (Ketek) is an oral erythromycin derivative ...
Telithromycin (Ketek) is an oral erythromycin derivative FDA-approved for treatment of mild to moderate community-acquired pneumonia, exacerbations of chronic bronchitis and acute bacterial sinusitis (Med Lett Drugs Ther 2004; 46:66). It is generally considered an alternative antibiotic because of its cost, potential for adverse effects including visual disturbances, exacerbation of myasthenia gravis, hepatotoxicity and drug interactions. A recent report (Ann Intern Med 2006; 144:415) described serious hepatotoxicity probably related to telithromycin in three patients, including one who died...
Med Lett Drugs Ther. 2006 Apr 24;48(1233):33 |  Show IntroductionHide Introduction

Tolterodine--A New Drug for Overactive Bladder

   
The Medical Letter on Drugs and Therapeutics • Oct 23, 1998  (Issue 1038)
, such as erythromycin or ketoconazole (Nizoral), the manufacturer recommends 1 mg b.i.d. A 30-day supply of Detrol at 2 ...
Tolterodine tartrate (Detrol - Pharmacia & Upjohn) is a new muscarinic receptor antagonist now being widely promoted for treatment of urinary frequency, urgency and urge incontinence caused by bladder (detrusor) overactivity.
Med Lett Drugs Ther. 1998 Oct 23;40(1038):101-2 |  Show IntroductionHide Introduction

Prevention and Treatment of Pertussis

   
The Medical Letter on Drugs and Therapeutics • Sep 17, 2012  (Issue 1399)
and erythromycin are alternatives. For patients who cannot take macrolide antibiotics, trimethoprim ...
The CDC has reported that many states are experiencing a higher-than-usual incidence of pertussis this year. The highest incidence has been in infants, but the disease has also occurred in older children, adolescents, and adults. Thirteen pertussis-related deaths were reported through August 24; the majority of these were in infants <3 months old.
Med Lett Drugs Ther. 2012 Sep 17;54(1399):73-4 |  Show IntroductionHide Introduction

Drug Interactions with Grapefruit Juice

   
The Medical Letter on Drugs and Therapeutics • Jan 05, 2004  (Issue 1173)
effect Diltiazem (Cardizem**) Possible toxicity Modest effect Erythromycin Possible increased toxicity ...
The ability of grapefruit juice to increase serum concentrations of drugs was first discovered during a study of the effect of ethanol on felodipine (Plendil) pharmacokinetics. Double-strength grapefruit juice used to disguise the taste of ethanol resulted in higher than expected serum concentrations of felodipine (DG Bailey et al, Clin Invest Med 1989; 12:357).
Med Lett Drugs Ther. 2004 Jan 5;46(1173):2-4 |  Show IntroductionHide Introduction

Treatment of Community-Associated MRSA Infections

   
The Medical Letter on Drugs and Therapeutics • Feb 13, 2006  (Issue 1228)
if the erythromycin-clindamycin D-zone test for resistance is positive. 8. Not recommended for pregnant women ...
Methicillin-resistant Staphylococcus aureus (MRSA) infections, which have been a concern for many years, previously occurred primarily in hospitalized patients and those recently treated with antibiotics. In the past few years, there has been an increasing incidence worldwide of community-associated (CA) MRSA infections in patients without recent antibiotic exposure or contact with the healthcare system.
Med Lett Drugs Ther. 2006 Feb 13;48(1228):13-4 |  Show IntroductionHide Introduction

Retapamulin (Altabax) - A New Topical Antibiotic

   
The Medical Letter on Drugs and Therapeutics • Feb 25, 2008  (Issue 1280)
and strep, such as cephalexin, dicloxacillin, clindamycin and amoxicillin/clavulanate. 6 Erythromycin ...
Retapamulin (re-tap'-a-mue'-lin; Altabax - Glaxo SmithKline) is a topical antibiotic recently approved by the FDA for treatment of bullous and non-bullous impetigo due to Streptococcus pyogenes and methicillin-susceptible Staphylococcus aureus. It is available as a 1% ointment by prescription only.
Med Lett Drugs Ther. 2008 Feb 25;50(1280):13-4 |  Show IntroductionHide Introduction

Dronedarone (Multaq) for Atrial Fibrillation

   
The Medical Letter on Drugs and Therapeutics • Oct 05, 2009  (Issue 1322)
) Droperidol (Inapsine) Table 3. Some Drugs that Prolong the QTc Interval* Erythromycin (Ery-Tab ...
Dronedarone (Multaq - Sanofi-Aventis) has been approved by the FDA for oral treatment of atrial fibrillation and flutter. Amiodarone (Cordarone, and others) is the most effective drug for this indication, but has considerable toxicity.
Med Lett Drugs Ther. 2009 Oct 5;51(1322):78-80 |  Show IntroductionHide Introduction

Everolimus and Pazopanib: Two New Drugs for Renal Cell Cancer

   
The Medical Letter on Drugs and Therapeutics • May 03, 2010  (Issue 1337)
not be used with P-glycoprotein inhibitors such as erythromycin (Ery-Tab, and others). CHOICE OF DRUGS ...
Everolimus (Afinitor – Novartis) and pazopanib (Votrient – GlaxoSmithKline), two oral multikinase inhibitors, have been approved by the FDA for treatment of advanced renal cell carcinoma. Sunitinib (Sutent) and sorafenib (Nexavar), two other oral multikinase inhibitors, and temsirolimus (Torisel), an IV multikinase inhibitor, were approved earlier for the same indication.
Med Lett Drugs Ther. 2010 May 3;52(1337):33-4 |  Show IntroductionHide Introduction

Roflumilast (Daliresp) for COPD

   
The Medical Letter on Drugs and Therapeutics • Jul 25, 2011  (Issue 1369)
that are inhibitors of CYP3A4 or inhibit both CYP3A4 and 1A2, such as cimetidine, erythromycin, ketoconazole ...
Roflumilast (Daliresp – Forest), an oral phosphodiesterase 4 (PDE4) inhibitor, was approved by the FDA to reduce the risk of exacerbations in adult patients with severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and a history of exacerbations.
Med Lett Drugs Ther. 2011 Jul 25;53(1369):59-60 |  Show IntroductionHide Introduction